FINNENCE ▪ THE WIRE FILE
THE WIRE · № 66009
SEC Filing■ Unclear/unknown
RTX filed 4 on 2026-10-05
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-05 00:00 UTC
LAST UPDATE2026-10-05 00:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 discloses insider transactions but the filing text gives no share count, price, or buy/sell direction.
Insider filing lacks detail to infer sentiment
CATALYST TO WATCH
Follow-up Form 4 detail on transaction type
MAIN RISK
Misreading routine insider filing as bearish
FULL DISPATCH
RTX (CIK 0001399738) filed a 4 on 2026-10-05.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTRTX · RTX
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — Genmab2026-10-05 12:00 UTC
New Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — Genmab2026-10-05 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 — Ambros Therapeutics, Inc.2026-10-05 12:00 UTC
New Phase 3 trial: Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 — Ambros Therapeutics, Inc.2026-10-05 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera — Agios Pharmaceuticals, Inc.2026-10-05 12:00 UTC
New Phase 3 trial: A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera — Agios Pharmaceuticals, Inc.2026-10-05 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma — Chiesi Farmaceutici S.p.A.2026-10-05 12:00 UTC
New Phase 3 trial: Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma — Chiesi Farmaceutici S.p.A.2026-10-05 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. — GL Pharm Tech Corporation2026-10-05 12:00 UTC
New Phase 3 trial: The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. — GL Pharm Tech Corporation2026-10-05 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: Lumateperone for the Prevention of Relapse in Patients With Schizophrenia — Intra-Cellular Therapies, Inc.2026-10-05 12:00 UTC
Phase 3 results posted: Lumateperone for the Prevention of Relapse in Patients With Schizophrenia — Intra-Cellular Therapies, Inc.2026-10-05 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.